-
Although drug-eluting stents (DES) have markedly reduced in-stent restenosis, it is not zero and it has not been uniform across different patient populations.
-
The DES had incomplete neointimal coverage 3-6 months after implantation, and this was associated with subclinical thrombus formation.
-
The appropriateness of implantable cardioverter defibrillator (ICD) therapy in patients with recent coronary revascularization has remained controversial.
-
Severe mitral regurgitation (MR) has long fascinated cardiovascular physicians.
-
-
In this paper, kindermann and colleagues describe a randomized cross-over study comparing right ventricular and biventricular pacing in patients with symptomatic bradycardia and impaired AV conduction.
-
Controlling healthcare costs is tricky business, and sometimes the best intentions have adverse outcomes, as pointed out in a new study in the June 1 New England Journal of Medicine
-
FDA Recommends Approval of Muraglitazar, But May Need To Reconsider; Which Antipsychotics Are More Dangerous?; Should CPOE Undergo Evaluation?; New Treatment for Tennis Elbow; FDA Actions
-
Given the impressive results of beta-blockers added to angiotensin-converting-enzyme (ACE) inhibitors in heart failure patients, many have suggested that had beta-blockers been studied first for heart failure, they would have been so impressive that we would start them before ACE inhibitors.
-
For the past 3 decades, beta-blockers have been first-line therapy for hypertension. However, recently the efficacy of beta-blockers for treating primary hypertension has been challenged. Thus, Lindholm and colleagues from Sweden conducted a meta-analysis of 13 randomized, controlled trials for the treatment of primary hypertension where a beta-blocker was used in at least 50% of the patients.
